

Vironix Health and Oxford University Generate Synthetic Data to Predict Health Deterioration

Vironix Health Inc. and Oxford University leverage AI for early virtual care management interventions to amplify patient well-being and reduce health costs.



AUSTIN, TX, UNITED STATES, October 31, 2024 /EINPresswire.com/ -- <u>Vironix Health</u> Inc., an innovative leader in Al-powered <u>virtual care management</u> applications for healthcare providers, is proud to report on its continuing successful collaborations with the <u>University of Oxford Mathematical Institute</u>. Most recently, Vironix scientists generated synthetic longitudinal health data to predict health deterioration from chronic diseases. Early interventions leveraging Al can amplify patient well-being, decelerate the disease progression, and reduce healthcare costs.

Dr. Georg Maierhofer, Hooke Research Fellow, said enthusiastically, "Our collaborations with Vironix continue to be successful in advancing the frontiers of predictive modeling in important disease prevention applications. In yet another successful project, we designed cutting-edge synthetic data generation algorithms with important implications in developing robust risk stratification models. These algorithms allow for proactive identification of health deterioration due to chronic kidney, lung, and heart diseases, while ensuring patient privacy remains a top priority." Benjamin Ballyk, MSc. Mathematical Modeling & Scientific Computing, University of Oxford noted, "My dissertation improves upon existing generative models to maximize the fidelity and privacy of synthetic clinical data. We are pleased to show a direct and promising application in chronic kidney disease data synthesis and look forward to extending these insights to new and pressing clinical avenues. This work would not be possible without Vironix's expansive technical and clinical expertise." Dr. Maierhofer added "We're excited to showcase the value of industry-academia partnerships in driving scientific innovation."

Dr. Sumanth Swaminathan, CEO of Vironix Health, commented on the partnership's potential, remarking, "Vironix continues its commitment to innovating preventive care technologies that prioritize validation through scientific rigor and peer review. Our alliance with Oxford leverages mathematics and machine-learning methods to prevent chronic disease exacerbations. We are honored to be Oxford's partner in this important and innovative research that contributes to ameliorating mortality, morbidity, and skyrocketing healthcare costs while elevating standards of

personalized care around the world."

About Oxford University, Mathematical Institute

The Mathematical Institute is part of the Mathematical, Physical and Life Sciences Division at the University of Oxford.

About Vironix Health Inc.

Vironix Health Inc., is recognized globally for its leadership with AI tools that predict health deterioration for Heart Failure, COPD, Asthma, Acute Respiratory Illness, and Chronic Kidney Disease.

To learn how you can benefit from Vironix Health Inc.'s expertise in Al-enhanced chronic disease management, visit: https://www.vironix.ai/.

Sumanth Swaminathan Vironix Health Inc. sswami@vironix.ai Visit us on social media:

X LinkedIn YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/755672251

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.